Compare Appian Corp (APPN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Eli Lilly And Co — how do they compare? Appian Corp trades at $35.5 (market cap $2.55B), while Eli Lilly And Co trades at $1,214.89 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 431.4× Appian Corp's market cap, and Eli Lilly And Co pays a 0.56% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | LLY | |
|---|---|---|
Market Cap | $2.55B | $1.10T |
Sector | Technology | Health |
52-Week High | $45.64 | $1.24K |
52-Week Low | $18.72 | $639.43 |
Enterprise Value | $2.68B | $1.14T |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) surged 13.91% to $34.64 following strong Q2 2026 earnings that exceeded expectations, with cloud subscription revenue growing 23% year-over-year. The stock trades near its pivot point of $34 with bullish technical signals from moving averages, though RSI levels suggest potential overbought conditions. Revenue growth has accelerated from $617M in 2024 to $727M in 2025, with the company achieving its first profitable year with $1.23M net income after several years of losses.
Appian demonstrates improving fundamentals with consistent revenue growth and recent profitability, though negative equity and high debt levels present risks. Analyst sentiment is mixed with 31.58% buy ratings but a consensus price target of $32.50 below current levels. The AI-driven workflow platform shows strong enterprise adoption, but investors should weigh growth potential against valuation concerns and competitive pressures in the low-code automation space.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
